Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

an "enriched" enrollment, double-blind, placebo-controlled, randomized withdrawal study measuring the efficacy and safety of BEMA Buprenorphine in patients with moderate to severe chronic pain.  Patients meeting the designated study criteria undergo titration with BEMA Buprenorphine to a dose that is both effective and well-tolerated.  Those patients who identify an effective and well tolerated dose are then randomized to either continue their BEMA Buprenorphine dose or begin use of a placebo (BEMA film with no active drug) for twelve weeks.  The primary efficacy measure is the mean change in pain intensity from the time patients are randomized (to BEMA Buprenorphine or placebo) through to the end of the twelve week study period.  The study design described has been utilized for a number of the opioid analgesics approved by the FDA in recent years.  The study design includes an interim analysis to confirm the number of patients needed for adequate statistical power.  This interim analysis is part of the study design agreed upon with FDA and is included solely to provide assurance that the sample size is adequate to detect the effect difference between the active and placebo treatments. 

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada,
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... clinical study to evaluate multiple ascending doses of NKTR-181, ... in development as a once- or twice-daily oral tablet ... to address the abuse liability and serious central nervous ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Intravenous ... http://www.reportlinker.com/p0611078/Global-Intravenous-IV-Solutions-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_E This report analyzes ... in US$ Million. The report provides separate ...
Cached Medicine Technology:Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6Global Intravenous (IV) Solutions Industry 2Global Intravenous (IV) Solutions Industry 3Global Intravenous (IV) Solutions Industry 4Global Intravenous (IV) Solutions Industry 5Global Intravenous (IV) Solutions Industry 6Global Intravenous (IV) Solutions Industry 7Global Intravenous (IV) Solutions Industry 8
(Date:8/30/2014)... “In 2013, a vehicle crash occurred every 5 ... a recently released article on 2013 Washington auto accident ... auto accident every 12 minutes, and a motorcyclist is involved ... the 2013 statistics, between now and this same time tomorrow, ... of an auto accident is real and impending - five ...
(Date:8/30/2014)... 30, 2014 Barton Associates, an industry ... locum tenens company , announces a new office location ... Barton Associates is headquartered in Peabody, MA, with additional ... and Jupiter, FL. , Barton Associates decided ... demand for healthcare providers. The United States is in ...
(Date:8/30/2014)... Saturday 30 August 2014: The first multidisciplinary recommendations ... acute coronary syndromes (ACS) are published today in ... was written jointly by the European Heart Rhythm ... and the European Association of Percutaneous Cardiovascular Interventions ... Bulent Gorenek (Turkey), chairperson of the task force, ...
(Date:8/30/2014)... The therapeutic benefit of revascularisation in coronary artery ... revascularisation guidelines presented at ESC Congress by joint ... the European Society of Cardiology (ESC) and Professor ... Cardio-Thoracic Surgery (EACTS). The joint guidelines are published ... (1), on the ESC Website (2), in EuroIntervention ...
(Date:8/29/2014)... 30, 2014 AGH Healthy Happenings, a ... Doctors in Delaware at Atlantic General Hospital, are ... services. In addition to no-cost blood pressure screenings at ... aid care at local sports tournaments. , In ... staff provide free disease management and falls prevention workshops ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... Strictly embargoed until: 00.01 GMT, Friday, 12 October, ... world,s,maternal mortality ratio (the number of maternal deaths per ... Development Goal (MDG),5, which aims to improve maternal health ... While an annual decline of 5.5 per cent in ...
... Calif., Oct. 11 Each year, more than,90,000 ... of gynecological cancer.,Although the overall death rate for ... cancer has increased slightly. Dr. Stan Wasbin, ... provides an overview of gynecological,cancer, stressing the importance ...
... little,cooler for the patients at Children,s National Medical Center, ... will make their annual,visit. The team will also launch ... Caps., Courage Caps are team-issued and branded hats ... games and online at NHL.com, with,100 percent of the ...
... Cancer researchers have long worked to understand why some ... to stop the production of testosterone and other androgens ... detected that androgen-synthesizing proteins are present within cancer cells, ... to produce their own androgens. , The presence ...
... School of Medicine have found that professional welders who ... at risk for loss of sense of smell. ... the first study to clearly demonstrate that welders who ... at risk for damaging their sense of smell, says ...
... 11 Six earthbound "angels" who have,brightened the lives ... Shield of Michigan. The Caring for Children Angel ... children,s lives. The awards have been,sponsored annually by the ... be honored at a Friday, Nov. 9 reception and ...
Cached Medicine News:Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 2Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 3Health News:The Silent Killer, Ovarian Cancer on Your Cancer Today (TM) 2Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Penn study suggests professional welders at risk for loss of sense of smell 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 45 degrees....
Titanium. 0.12 mm 1 x 2 teeth with 6 mm platform and 2.0 mm angled tips. Flat serrated handle, dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Narrow 4 mm long smooth platform. Serrated handle with polished finish....
Medicine Products: